Abstract: The invention pertains to the use of therapeutically effective amounts of (a) (i) vitamin C and/or selenium and (ii) at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof; or (b) (i) vitamin C and/or selenium and (iii) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; or (c) a combination of (i), (ii) and (iii); wherein (a), (b) or (c) optionally further comprises vitamin E, in the manufacture of a product for therapeutically improving synaptic connectivity and/or therapeutically supporting memory and/or cognitive function in a human subject in need thereof.

Abstract: Provided in some embodiments are titration packages, kits, and methods of treating pulmonary arterial hypertension comprising prescribing and/or administering to a patient in need thereof 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, via a titration scheme that comprises the up-titration of Compound 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, over a period of no more than about nine weeks until an optimized dose is administered.

Abstract: A method of producing cell derived particles is disclosed. The method comprising isolating cell-derived particles from a biological sample comprising cells modified to present CD24 so as to obtain a preparation of the cell-derived particles substantially devoid of intact cells. Cell derived particles, a culture medium and a cell culture are also disclosed.

Abstract: Disclosed is a method for assessing a cognition and movement disease or disorder in a subject. In the method, a qualimetric activity parameter for cognition and/or fine motoric activity measurements is determined from a dataset of measurements obtained from the subject using a mobile device. The qualimetric activity parameter is compared to a reference and the disease or disorder is thereby assessed. A method identifying whether a subject will benefit from a therapy for a cognition and movement disease or disorder is also disclosed. The method can be carried out with a mobile device having a processor, a sensor and a database as well as software that carries out the method. Also disclosed is a system having a mobile device with a sensor and a remote device having a processor and a database and software that carries out the method for assessing a cognition and movement disease or disorder.

Abstract: An example of an apparatus is provided. The apparatus includes a power sensor to measure a power used to emit light. In addition, the apparatus includes a light source controller to control a light source to change an intensity of the light emitted by the light source. Furthermore, the apparatus includes a boundary detector to detect a room boundary. The apparatus also includes a device sensor to determine a position of a proximate device. The apparatus further includes a communications interface to communicate with the proximate device to transmit measured data to the proximate device and to receive device data from the proximate device. Also, the apparatus includes a processor to calculate a lighting power density based on the proximate device data and the measured data. The lighting power density is to be used by the light source controller to adjust the power used to emit the light.

Abstract: Systems and methods relate to transgenic organisms and their use as biosensors are described. In some embodiments, the systems and methods include a first population of transgenic organisms that includes a first constitutively expressed reporter gene, and a first transgene that includes a first inducible promoter from a response pathway gene, wherein the first inducible promoter is coupled to a first reporter gene. Other embodiments are described.

Abstract: The disclosure relates to compositions comprising isolated mitochondria or combined mitochondrial agents, and methods of treating disorders using such compositions.

Abstract: A machine-based learning system for predicting the presence of lesions indicative of axial spondyloarthritis in medical imaging data includes an image processor for receiving and processing one or more MRI image data set containing pelvic region and sacroiliac joint of a subject, and dividing said MRI image data set into a set of 3D voxels. The system also includes a voxel classifier for calculating for each of said the voxels one or more class probabilities of such voxel to contain a lesion of a particular type or being a non-lesion. The system also includes a lesion probability map generator for receiving the data produced by the voxel classifier and producing a probability intensity map for each of lesion types, in which one or more areas classified as lesion are highlighted; and an image display for displaying the output of the lesion probability map generator.

Abstract: Historical information is accessed that describes a previous state of a field, previous environmental conditions for the field, and previous farming machine actions performed in the field. A tank management model is applied to the historical information to determine expected weed densities within field portions and an amount of treatment fluid required to treat plants within the field. While the farming machine is treating plants in the field, current information describing a current state of the field is accessed. The tank management model is applied to the current information to determine updated weed densities within field portions not yet treated. The farming machine performs a modified plant treatment action based on the updated weed densities and a comparison of a remaining amount of treatment fluid within a tank of the farming machine and an updated amount of treatment fluid for treating plants within field portions not yet treated.

Abstract: The present invention relates to compositions and methods utilizing anti-TNF antibodies having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37 for use in the safe and effective treatment of active Psoriatic Arthritis (PsA).

Abstract: Systems and methods for statistically-representative sample data generation are disclosed. For example, a sample-data generator and/or a data discriminator may be received by a system, which may utilize the sample-data generator to generate sample data. The data discriminator may be utilized to train the sample-data generator until the data discriminator cannot discriminate between data received from the sample-data generator and data received by a database associated with the system. The trained sample-data generator may be sent to other systems, which may generate and utilize, such as for prediction model training, statistically-representative sample data generated by the trained sample-data generator.

Abstract: A nanomedicinal composition comprising a nanocarrier and an antioxidant. The nanocarrier contains a metal organic framework and a porous silicate and/or aluminosilicate matrix. The antioxidant is disposed in the pores and/or on the surface of the nanocarrier by a solution phase impregnation process. The nanomedicinal composition is used in a method of treating Blastocystis infection.

Abstract: A composition for enhancing the production of a homeoprotein includes an inhibitor of lysosomal function. A method for enhancing the production of a homeoprotein, includes treating cells with an inhibitor of lysosomal function, a method for producing an animal cell line continuously expressing a homeoprotein and a method for mass-producing a homeoprotein using the animal cell line.

Abstract: The invention features devices and kits for capturing and culturing microorganisms (e.g., bacteria, fungi, or protists) and methods of using the devices and kits to detect microorganisms in environmental and other samples. The device includes a nutrient media having a flat growth area on which microorganisms can grow. Samples are collected by contacting the device with any environmental sample, e.g., rolling device on a work surface or exposing device to air, or by filtering a sample through a membrane. Microorganisms deposited on the membrane derive nutrients from the underlying media and grow into colonies that can then be detected using methods known in the art. The detected colonies can be imaged digitally or with film.

Abstract: Methods and systems for storing and managing biosystem on a chip data disclosed. To store the data, operation data from the biosystem on a chip may be stored in a database. To manage use of the stored data, a graph representation of the biosystem on a chip. The nodes of the graph representation may correspond to the architectural features of the biosystem on a chip. The edges between the nodes may be based on whether the corresponding architectural features are in communication with one another. Each of the nodes may be associated with pointers that point to portions of the operation data in the database that is relevant to the architecture feature associated with the respective node.

Abstract: A method of training a rodent to identify pairs of same or different odors, whereby the rodent learns the rule irrespective of the particular odors. Once trained, the rodent can be used to measure perceptual odor similarities between members of pairs of odors, which odors may be unrelated to the odors the rodent was trained on.

Abstract: Provided is a method of monitoring a heart rate of an open circulatory system aquatic organism including water fleas, zebrafish, brine shrimp, and the method of evaluating individual response by real time measurement of a heart rate of an aquatic organism and the individual response evaluation apparatus by real time measurement of a heart rate of an aquatic organism according to the present invention may effectively fix the aquatic organism for real time measurement of the heart rate of an aquatic organism, and may measure the heart rate using digital holography to display the heart rate while configuring a data format to allow the corresponding data to be stored for a long time, thereby treating a compound for inducing an individual response, securing a heart rate change in real time by image processing, and then effectively determining the presence or absence of harmfulness due to induction of the individual response.

Abstract: An optimized protein-free tripartite vaccine that protects against lethal blood and lung infections caused by a variety of nosocomial pathogens across taxonomic kingdoms, including Gram-positive bacteria, Gram-negative bacteria, and fungi.

Abstract: The present invention relates to a novel use of NCKAP1 gene in neurodegenerative diseases. More specifically, the present invention relates to a marker composition for predicting the prognosis of a neurodegenerative disease, comprising a NCKAP1 protein or a gene encoding same, a composition and a kit for predicting the prognosis of a neurodegenerative disease, which comprises a formulation for measuring the level of the protein or an mRNA of the gene encoding same, and a pharmaceutical composition for preventing or treating neurodegenerative disease, comprising the protein or the gene encoding same as an active ingredient.

Abstract: The invention pertains to the use of therapeutically effective amounts of (a) (i) vitamin C and/or selenium and (ii) at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof; or (b) (i) vitamin C and/or selenium and (iii) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; or (c) a combination of (i), (ii) and (iii); wherein (a), (b) or (c) optionally further comprises vitamin E, in the manufacture of a product for therapeutically improving synaptic connectivity and/or therapeutically supporting memory and/or cognitive function in a human subject in need thereof

Abstract: SIRP1alpha-41BBL fusion proteins are provided. Accordingly, there is provided a SIRPalpha-41BBL fusion protein comprising a single amino acid linker between the SIRPalpha and the 41BBL. Also there is provided a SIRPalpha-41BBL fusion protein in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the SIRP1alpha-41BBL fusion protein, host-cells expressing the SIRP1alpha-41BBL fusion protein and methods of use thereof.

Abstract: The aspects of the disclosed embodiments relate to method for determining a likelihood of an inflammatory gastrointestinal tract disease. The method includes diluting a biological sample of a human subject and contacting it with 8-anilinonaphthalene-1-sulfonic acid as modulating agent and further with a reagent, said reagent comprising a peroxidase enzyme and a label selected from a europium chloride and terbium chloride. The sample is incubated and excited, and the time-resolved luminescence signal of the label in the sample is measured. If the luminescence signal is at least 112% higher than for a control sample from a human so subject without of an inflammatory intestine disease, an increased likelihood of an inflammatory intestine disease of the human subject is determined.

Abstract: A nanomedicinal composition comprising a nanocarrier and an antioxidant. The nanocarrier contains a metal organic framework and a porous silicate and/or aluminosilicate matrix. The antioxidant is disposed in the pores and/or on the surface of the nanocarrier by a solution phase impregnation process. The nanomedicinal composition is used in a method of treating Blastocystis infection.

Abstract: Provided herein is technology relating to immunoisolation of cells and tissues, including, but not exclusively, to compositions, methods, and kits for encapsulating cells and/or tissues within an immunoisolating device to protect the cells/or tissues from host immune rejection.

Abstract: The invention provides compositions, methods, and systems for using cell-free RNA for improved detection of rare cells and/or species that are useful for diagnosing and/or monitoring cancer. The invention also provides for compositions, methods, and systems for early detection of cells that are resistant and/or developing resistance to cancer therapies.

Abstract: The present invention provides a strain of Bacteroides thetaiotaomicron and derivatives thereof, and the use of said strain or derivatives in treating inflammatory, autoimmune and allergic disorders. The invention also provides pharmaceutical compositions, nutritional supplements, feedstuffs, food products, dietary supplements, and food additives comprising said strain or derivatives.

Abstract: The present invention further relates to using vaccinia virus complement control protein (VCP), factor H and/or a complement control protein (CCP)-containing protein as modulator of the entry and/or replication of pathogen(s), wherein the pathogen is a virus or bacteria. The present invention further relates to a method of prevention and/or treatment of influenza A virus (IAV) infection in a subject of need thereof and to a method of modulation of the entry and/or replication of pathogen(s) in a subject of need thereof.

Abstract: Presented herein are methods for treating spinal disc degeneration (SDD) by administering to a subject in need thereof, an amount of a SHH signaling pathway activator effective for treating the subject.

Abstract: Provided herein are compositions and methods comprising microbiome biomarkers of responsiveness/resistance to immunotherapy (e.g., anti-PD1/PD-L1 therapy), and diagnostic, prognostic and therapeutic uses thereof. In particular, the amount, identity, presence, and/or ratio of microflora in the microbiome of a subject is used to determine the responsiveness/resistance of the subject to immunotherapy, and/or the microbiome of a subject is manipulated to enhance the responsiveness of the subject to various immunotherapies and co-therapies.

Abstract: An ingestible capsule for detecting cancerous and non-cancerous tissues in a colon of patient is disclosed. The capsule has a radiation source integrated into the capsule body for illuminating tissues within a colon of the patient. Tissues of the colon are irradiated with radiation from the radiation source to elicit a fluorescence response, and a photon detector measures photons of the fluorescence response. Intensity and fluorescence lifetime of the fluorescence response is determined based on measured photons. A system employing the capsule is configured to distinguish cancerous and non-cancerous tissues based on the determined fluorescence lifetime of the fluorescence response.

Abstract: The present application relates to compositions comprising 4-chloroindole-3-acetic acid (4Cl-IAA) or an analogue thereof, or a combination of the latter, in the form of a potassium salt, a sodium salt or an amine salt. For example, such compositions can be used used in methods for selectively causing damage or mortality to weed.

Abstract: The disclosure provides methods and compositions that are useful to lessen and/or cure bacterial biofilms and treat diseases or disorders associated with biofilms using one or more novel polypeptide vaccines, antibodies, antibody fragments and compositions. Bacteria that cannot form functional biofilms are more readily cleared by the remainder of the host's immune system and/or traditional antibiotics.

Abstract: Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.

Abstract: The present invention relates to compositions forming a low viscosity mixture of: a) 20-80 wt. % of at least one diacyl glycerol and/or a tocopherol; b) 20-80 wt. % of at least one phosphatidyl choline (PC); c) 5-20 wt. % of at least one biocompatible, organic mono-alcoholic solvent; d) up to 20 wt. % polar solvent e) at least one peptide active agent; f) optionally at least one antioxidant; wherein the ratio of components a:b is in the range 40:60 to 54:46; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations.

Abstract: The present invention relates generally to methods and kits for detecting one or more biomarkers, such as an Epidermal Growth Factor Receptor (EGFR) mutation, e.g., T790M mutation, L858R mutation, one or more exon19 insertions and/or one or more exon19 deletions in the EGFR gene, in a biological sample to aid in diagnosis, prognosis, monitoring, or therapy selection for a disease such as, for example, cancer. The methods and kits are useful in aiding in diagnosis, prognosis, monitoring, or therapy selection for lung cancer, e.g., non-small cell lung cancer (NSCLC).

Abstract: Disclosed is a method of determining efficacy of a cosmetic composition to inhibit an atmospheric pollutant from contacting skin, comprising the steps of: (i) filling a sample holder of known dimensions with known amount of said composition to form a layer of defined thickness therein, where said sample holder is amenable to fluorescence-based assay; (ii) depositing, on said layer, a known amount of a model fine particulate matter which resembles an atmospheric pollutant at least in size and which comprises a material responsive to fluorescence microscopy which is excitable by a wavelength (?ex) and which emits radiation (?em) where (?ex)?(?em); (iii) irradiating said composition and said model fine particulate matter by said ?ex and recording intensity of fluorescence at ?em a plurality of times for a defined period during which said model fine particulate matter interacts with said layer; and, (iv) determining, corrected intensity of fluorescence at ?em by the following equation; corrected Intensity=recorde

Abstract: Methods of treating or preventing microbial infection in a subject in need of treatment by administering a therapeutically effective amount of ergothioneine, or functional analog, or prodrug, or salt thereof. Ergothioneine may be advantageously administered in conjunction with lactoferrin.

Abstract: A method of predicting the responsiveness of a patient to a pharmaceutical drug by measuring metabolites in a biological sample from the patient is disclosed. Specific drug metabolites in blood from breast cancer patients are analyzed using NMR spectroscopy whereby responsiveness of the human cancer patients before, during and after treatment with a cancer drug is assessed by measuring the change in clinical outcomes. Data obtained is used to identify particular NMR resonances that are strongly correlated with whether the patient is responsive or resistant to each drug. As such, models for predicting the responsiveness of a patient to each drug based on metabolites from the patient are provided.

Abstract: Methods of enhancing biomass and secondary metabolite accumulation of microalgal species are described herein. A cell culture of the microalgal species were elicited using a combination of techniques for a period of time. Experimental studies compared biomass dry weight production, chlorophyll dry weight content and astaxanthin dry weight content between controls and elicitation treatments. The present invention demonstrated that combined elicitation is an effective method for improving cell biomass growth and astaxanthin production.

Abstract: Provided herein are custom therapeutic compositions combining select Chinese herbs and strains of Cannabis, methods of making the compositions, and methods of using the composition for treatment of headache pain.

Abstract: The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 Receptor Binding Domain (SARS-CoV-2-RBD) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (COVID-19). Embodiments include the administration of the fusion proteins to patients that have recovered from COVID-19 as a booster vaccination, to antibody naïve patients to produce antibodies to the SARS-CoV-2 virus to enable the patients to become convalescent plasma donors, to patients who have been infected by the SARS-CoV-2 virus and have contracted COVID-19 in order to limit the scope of the infection and ameliorate the disease, and as a prophylactic COVID-19 vaccine. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

Abstract: The invention relates to pharmaceutical compositions that contain COVID-19 peptide specific cytotoxic T cells, and to methods for treating or preventing COVID-19 infection.

Abstract: Provided herein are methods for treating melanoma in a subject.

Abstract: Provided herein are methods and compositions for preventing and treating damage to the heart subsequent to myocardial infarction (MI) resulting from harmful fibrotic remodeling, thereby improving cardiac function and reducing mortality from subsequent heart failure.

Abstract: Biocompatible polymeric nanoparticles may include: a biocompatible polymer and/or functional metal nanostructures. The biocompatible polymer may be a polyhydroxyalkanoate (PHA). The functional metal nanostructures may include at least one noble metal, at least one magnetic metal oxide, or mixtures thereof. The biocompatible polymeric nanoparticles may have an average size less than or equal to 200 nanometers (nm).

Abstract: Provided herein are composition comprising novel epitopes of ApoB100, as well as sub-sequences, portions and modifications thereof, and uses thereof for treating adverse cardiovascular events, cardiovascular disease, atherosclerosis and certain liver disorders.

Abstract: Provided herein are methods and compositions for disrupting biofilms in vitro and in vivo. Also disclosed are antibodies comprising a specified heavy chain (HC) immunoglobulin variable domain sequence and/or a specified light chain (LC) immunoglobulin variable domain sequence.

Abstract: The present application relates to compositions comprising an iodinated contrast agent and indocyanine green co-encapsulated inside a liposomal carrier, various uses thereof as well as methods for their preparation.

Abstract: An information processing apparatus, an information processing method, and an information processing program which are capable of suppressing an increase in consumption of system resources used for suppressing a spread of an infection disease are acquired. An information processing apparatus includes an acquisition unit that acquires information regarding an infection disease of a first animal infected with the infection disease, a specification unit that specifies a second animal positioned within a behavior area of the first animal, a determination unit that determines whether or not the infection disease of the first animal is likely to infect the second animal, and a notification unit that notifies an owner of the second animal of an alarm regarding the infection disease in a case where it is determined that the infection disease of the first animal is likely to infect the second animal.

Abstract: The invention relates to a device for assessing the characteristics of the swallowing process in a subject a sensor that is capable of detecting vibrations of the throat during swallowing.